ATC Group: A16AB02 Imiglucerase

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of A16AB02 in the ATC hierarchy

Level	Code	Title
`1`	A	Alimentary tract and metabolism
`2`	A16	Other alimentary tract and metabolism products
`3`	A16A	Other alimentary tract and metabolism products
`4`	A16AB	Enzymes
`5`	A16AB02	Imiglucerase

Defined daily dose

The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.

Code	Route	Amount	Notes
PAREN	Parenteral	300 [iU]

Active ingredients in A16AB02

Active Ingredient
Imiglucerase
Imiglucerase is a recombinant macrophage targeted acid β-glucosidase that replaces the deficient enzyme activity, hydrolysing glucosylceramide, thus correcting initial pathophysiology and preventing secondary pathology. Imiglucerase has been shown to improve both mental and physical aspects in the quality of life of Gaucher disease.